Parvovirus vectors: Use and optimisation in cancer gene therapy

Expert Reviews in Molecular Medicine

Volumn 6, Issue 16, 2004, Pages

  Blechacz, Boris ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

Author keywords

AAV; ARP; Cancer gene therapy; Parvovirus; Viral vector

Indexed keywords

ALBUMIN; ALDEHYDE DEHYDROGENASE; ALPHA 1 ANTITRYPSIN; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTIDINE DEAMINASE; CYTOTOXIC AGENT; DIHYDROFOLATE REDUCTASE; DIHYDROPYRIMIDINE DEHYDROGENASE; GANCICLOVIR; GLUTATHIONE TRANSFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MONOCYTE CHEMOTACTIC PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PARVOVIRUS VECTOR; THYMIDINE KINASE; VASCULOTROPIN RECEPTOR 2; VIRUS PROTEIN; ANGIOGENESIS INHIBITOR; RECOMBINANT VACCINE;

ADENO ASSOCIATED VIRUS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL CULTURE; CANCER GENETICS; CANCER MORTALITY; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; EX VIVO STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; INCIDENCE; LIFE CYCLE; NEPHROBLASTOMA; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; T LYMPHOCYTE; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; ENZYMOLOGY; EVALUATION; GENE REPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; PATHOGENICITY; PHYSIOLOGY; SUICIDE TRANSGENE; VIRUS REPLICATION;

ADENO-ASSOCIATED VIRUS; PARVOVIRIDAE; PARVOVIRUS;

ANGIOGENESIS INHIBITORS; CANCER VACCINES; DEPENDOVIRUS; GENE TARGETING; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; GENOME, VIRAL; HEMATOPOIETIC STEM CELLS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; ORGAN SPECIFICITY; PARVOVIRUS; SUPPRESSION, GENETIC; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 31044439428     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399404008026     Document Type: Review

References (232)

1. WHO (2003) World Cancer Report, World Health Organisation
2. Miller, A.D. (2004) Nonviral liposomes. Methods Mol Med 90, 107-137,
3. Ogris, M. and Wagner, E. (2002) Tumor-targeted gene transfer with DNA polyplexes. Somat Cell Mol Genet 27, 85-95,
4. Maurer, N., Fenske, D.B. and Cullis, P.R. (2001) Developments in liposomal drug delivery systems. Expert Opin Biol Ther 1, 923-947,
5. Niidome, T. and Huang, L. (2002) Gene therapy progress and prospects: nonviral vectors. Gene Ther 9, 1647-1652,
6. Nishikawa, M. and Huang, L. (2001) Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 12, 861-870,
7. Peng, K.W. et al. (2003) Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 101, 2557-2562,
8. Peng, K.W. et al. (2002) Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 62, 4656-4662,
9. Peng, K.W. et al. (2001) Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98, 2002-2007,
10. Dingli, D. et al. (2003) Genetically targeted radiotherapy for multiple myeloma. Blood 102, 489-496,
11. Berns, K.I. (1996) Parvoviridae: The viruses and their replication. In Virology (Fields, B.N.K.D. et al., eds), pp. 2173-2197, Lippincott-Raven, Philadelphia
12. Xie, Q. et al. (2002) The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A 99, 10405-10410,
13. Buning, H. et al. (2003) Receptor targeting of adeno-associated virus vectors. Gene Ther 10, 1142-1151,
14. Agbandje-McKenna, M. et al. (1998) Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure 6, 1369-1381,
15. Cotmore, S.F. and Tattersall, P. (1995) DNA replication in the autonomous parvoviruses. Semin Virol 6, 271-281,
16. Cotmore, S.F. and Tattersall, P. (1987) The autonomously replicating parvoviruses of vertebrates. Adv Virus Res 33, 91-174,
17. Pintel, D. et al. (1983) The genome of minute virus of mice, an autonomous parvovirus, encodes two overlapping transcription units. Nucleic Acids Res 11, 1019-1038,
18. Astell, C.R. et al. (1983) The complete DNA sequence of minute virus of mice, an autonomous parvovirus. Nucleic Acids Res 11, 999-1018,
19. Astell, C.R. et al. (1983) Structure and replication of minute virus of mice DNA. Cold Spring Harb Symp Quant Biol 47 Pt 2, 751-762,
20. Cotmore, S.F. et al. (1986) Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. J Virol 60, 548-557,
21. Cotmore, S.F. and Tattersall, P. (1986) Organization of nonstructural genes of the autonomous parvovirus minute virus of mice. J Virol 58, 724-732,
22. Spegelaere, P. et al. (1991) Initiation of transcription from the minute virus of mice P4 promoter is stimulated in rat cells expressing a c-Ha-ras oncogene. J Virol 65, 4919-4928,
23. Rhode, S.L., 3rd (1985) trans-Activation of parvovirus P38 promoter by the 76K noncapsid protein. J Virol 55, 886-889,
24. Cziepluch, C. et al. (1998) Identification of a novel cellular TPR-containing protein, SGT, that interacts with the nonstructural protein NS1 of parvovirus H-1. J Virol 72, 4149-4156,
25. Cziepluch, C. et al. (2000) H-1 parvovirus-associated replication bodies: a distinct virus-induced nuclear structure. J Virol 74, 4807-4815,
26. Bodendorf, U. et al. (1999) Nuclear export factor CRM1 interacts with nonstructural proteins NS2 from parvovirus minute virus of mice. J Virol 73, 7769-7779,
27. Cotmore, S.F. et al. (1995) The NS1 polypeptide of the murine parvovirus minute virus of mice binds to DNA sequences containing the motif [ACCA]2-3. J Virol 69, 1652-1660,
28. Nuesch, J.P., Cotmore, S.F. and Tattersall, P. (1995) Sequence motifs in the replicator protein of parvovirus MVM essential for nicking and covalent attachment to the viral origin: identification of the linking tyrosine. Virology 209, 122-135,
29. Cotmore, S.F. and Tattersall, P. (1998) High-mobility group 1/2 proteins are essential for initiating rolling-circle-type DNA replication at a parvovirus hairpin origin. J Virol 72, 8477-8484,
30. Christensen, J., Cotmore, S.F. and Tattersall, P. (2001) Minute virus of mice initiator protein NS1 and a host KDWK family transcription factor must form a precise ternary complex with origin DNA for nicking to occur. J Virol 75, 7009-7017,
31. Skiadopoulos, M.H. et al. (1992) Characterization of linker insertion and point mutations in the NS1 gene of minute virus of mice: effects on DNA replication and transcriptional activation functions of NS-1. Virology 188, 122-134,
32. Caillet-Fauquet, P. et al. (1990) Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding nonstructural proteins. Embo J 9, 2989-2995,
33. Ozawa, K. et al. (1988) The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 62, 2884-2889,
34. Brownstein, D.G. et al. (1992) The pathogenesis of infection with minute virus of mice depends on expression of the small nonstructural protein NS2 and on the genotype of the allotropic determinants VP1 and VP2. J Virol 66, 3118-3124,
35. Cotmore, S.F. et al. (1997) The NS2 polypeptide of parvovirus MVM is required for capsid assembly in murine cells. Virology 231, 267-280,
36. Li, X. and Rhode, S.L., 3rd (1993) The parvovirus H-1 NS2 protein affects viral gene expression through sequences in the 3′ untranslated region. Virology 194, 10-19,
37. Li, X. and Rhode, S.L., 3rd (1991) Nonstructural protein NS2 of parvovirus H-1 is required for efficient viral protein synthesis and virus production in rat cells in vivo and in vitro. Virology 184, 117-130,
38. Naeger, L.K., Cater, J. and Pintel, D.J. (1990) The small nonstructural protein (NS2) of the parvovirus minute virus of mice is required for efficient DNA replication and infectious virus production in a cell-type-specific manner. J Virol 64, 6166-6175,
39. Eichwald, V. et al. (2002) The NS2 proteins of parvovirus minute virus of mice are required for efficient nuclear egress of progeny virions in mouse cells. J Virol 76, 10307-10319,
40. Brandenburger, A. et al. (1990) NS-1 and NS-2 proteins may act synergistically in the cytopathogenicity of parvovirus MVMp. Virology 174, 576-584,
41. Legrand, C., Rommelaere, J. and Caillet-Fauquet, P. (1993) MVM(p) NS-2 protein expression is required with NS-1 for maximal cytotoxicity in human transformed cells. Virology 195, 149-155,
42. Ahn, J.K., Pitluk, Z.W. and Ward, D.C. (1992) The GC box and TATA transcription control elements in the P38 promoter of the minute virus of mice are necessary and sufficient for transactivation by the nonstructural protein NS1. J Virol 66, 3776-3783,
43. Christensen, J., Cotmore, S.F. and Tattersall, P. (1995) Minute virus of mice transcriptional activator protein NS1 binds directly to the transactivation region of the viral P38 promoter in a strictly ATP-dependent manner. J Virol 69, 5422-5430,
44. Lorson, C. and Pintel, D.J. (1997) Characterization of the minute virus of mice P38 core promoter elements. J Virol 71, 6568-6575,
45. Lorson, C. et al. (1996) Efficient transactivation of the minute virus of mice P38 promoter requires upstream binding of NS1. J Virol 70, 834-842,
46. Kotin, R.M. et al. (1990) Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 87, 2211-2215,
47. Kotin, R.M., Linden, R.M. and Berns, K.I. (1992) Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. Embo J 11, 5071-5078,
48. Samulski, R.J. et al. (1991) Targeted integration of adeno-associated virus (AAV) into human chromosome 19. Embo J 10, 3941-3950,
49. Brown, K.E., Anderson, S.M. and Young, N.S. (1993) Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262, 114-117,
50. Weigel-Kelley, K.A., Yoder, M.C. and Srivastava, A. (2001) Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol 75, 4110-4116,
51. Weigel-Kelley, K.A., Yoder, M.C. and Srivastava, A. (2003) Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 102, 3927-3933,
52. Parker, J.S. et al. (2001) Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J Virol 75, 3896-3902,
53. Govindasamy, L. et al. (2003) Structures of host range-controlling regions of the capsids of canine and feline parvoviruses and mutants. J Virol 77, 12211-12221,
54. Hueffer, K. et al. (2003) The natural host range shift and subsequent evolution of canine parvovirus resulted from virus-specific binding to the canine transferrin receptor. J Virol 77, 1718-1726,
55. Hueffer, K. et al. (2003) Combinations of two capsid regions controlling canine host range determine canine transferrin receptor binding by canine and feline parvoviruses. J Virol 77, 10099-10105,
56. Qing, K. et al. (1999) Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5, 71-77,
57. Summerford, C., Bartlett, J.S. and Samulski, R.J. (1999) AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 5, 78-82,
58. Duan, D. et al. (1999) Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 73, 10371-10376,
59. Parker, J.S. and Parrish, C.R. (2000) Cellular uptake and infection by canine parvovirus involves rapid dynamin-regulated clathrin-mediated endocytosis, followed by slower intracellular trafficking. J Virol 74, 1919-1930,
60. Hansen, J., Qing, K. and Srivastava, A. (2001) Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts. J Virol 75, 4080-4090,
61. Lai, C.M., Lai, Y.K. and Rakoczy, P.E. (2002) Adenovirus and adeno-associated virus vectors. DNA Cell Biol 21, 895-913,
62. Richards, R.G. and Armentrout, R.W. (1979) Early events in parvovirus replication: lack of integration by minute virus of mice into host cell DNA. J Virol 30, 397-399,
63. Rommelaere, J. and Cornelis, J.J. (2001) Autonomous Parvoviruses. In Replication-Competent Viruses for Cancer Therapy 22) (Hernáiz Driever, P.and Rabkin, S.D., eds), pp. 100-129, Karger, Basel
64. Gao, G.P. et al. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99, 11854-11859,
65. Bultmann, B.D. et al. (2003) Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch 442, 8-17,
66. Rommelaere, J. and Cornelis, J.J. (1991) Antineoplastic activity of parvoviruses. J Virol Methods 33, 233-251,
67. Dupressoir, T. et al. (1989) Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res 49, 3203-3208,
68. Faisst, S. et al. (1998) Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection. Int J Cancer 75, 584-589,
69. Toolan, H.W. and Ledinko, N. (1968) Inhibition by H-1 virus of the incidence of tumors produced by adenovirus 12 in hamsters. Virology 35, 475-478,
70. Guetta, E. et al. (1990) Selective killing of transformed rat cells by minute virus of mice does not require infectious virus production. J Virol 64, 458-462,
71. Chen, Y.Q. et al. (1989) Sensitization of human keratinocytes to killing by parvovirus H-1 takes place during their malignant transformation but does not require them to be tumorigenic. Carcinogenesis 10, 163-167,
72. Cornelis, J.J. et al. (1990) Susceptibility of human cells to killing by the parvoviruses H-1 and minute virus of mice correlates with viral transcription. J Virol 64, 2537-2544,
73. Cornelis, J.J. et al. (1988) Sensitization of transformed rat fibroblasts to killing by parvovirus minute virus of mice correlates with an increase in viral gene expression. J Virol 62, 3438-3444,
74. Chen, Y.Q. et al. (1986) Selective killing of simian virus 40-transformed human fibroblasts by parvovirus H-1. Cancer Res 46, 3574-3579,
75. Cornelis, J.J. et al. (1988) Transformation of human fibroblasts by ionizing radiation, a chemical carcinogen, or simian virus 40 correlates with an increase in susceptibility to the autonomous parvoviruses H-1 virus and minute virus of mice. J Virol 62, 1679-1686,
76. Van Pachterbeke, C. et al. (1993) Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int J Cancer 55, 672-677,
77. Mousset, S. and Rommelaere, J. (1982) Minute virus of mice inhibits cell transformation by simian virus 40. Nature 300, 537-539,
78. Toolan, H. and Ledinko, N. (1965) Growth and cytopathogenicity of H-viruses in human and simian cell cultures. Nature 208, 812-813,
79. Salome, N. et al. (1990) Sensitization of transformed rat cells to parvovirus MVMp is restricted to specific oncogenes. Oncogene 5, 123-130,
80. Fuks, F. et al. (1996) ras oncogene-dependent activation of the P4 promoter of minute virus of mice through a proximal P4 element interacting with the Ets family of transcription factors. J Virol 70, 1331-1339,
81. Perros, M. et al. (1995) Upstream CREs participate in the basal activity of minute virus of mice promoter P4 and in its stimulation in rastransformed cells. J Virol 69, 5506-5515,
82. Bashir, T., Rommelaere, J. and Cziepluch, C. (2001) In vivo accumulation of cyclin A and cellular replication factors in autonomous parvovirus minute virus of mice-associated replication bodies. J Virol 75, 4394-4398,
83. Deleu, L. et al. (1998) Opposite transcriptional effects of cyclic AMP-responsive elements in confluent or p27KIP-overexpressing cells versus serum-starved or growing cells. Mol Cell Biol 18, 409-419,
84. Deleu, L. et al. (1999) Activation of promoter P4 of the autonomous parvovirus minute virus of mice at early S phase is required for productive infection. J Virol 73, 3877-3885,
85. Legendre, D. and Rommelaere, J. (1992) Terminal regions of the NS-1 protein of the parvovirus minute virus of mice are involved in cytotoxicity and promoter trans inhibition. J Virol 66, 5705-5713,
86. Astell, C.R. et al. (1996) Minute virus of mice cisacting sequences required for genome replication and the role of the trans-acting viral protein, NS1. Prog Nucleic Acid Res Mol Biol 55, 245-285,
87. Op De Beeck, A. and Caillet-Fauquet, P. (1997) Viruses and the cell cycle. Prog Cell Cycle Res 3, 1-19,
88. Op De Beeck, A. and Caillet-Fauquet, P. (1997) The NS1 protein of the autonomous parvovirus minute virus of mice blocks cellular DNA replication: a consequence of lesions to the chromatin? J Virol 71, 5323-5329,
89. Ohshima, T. et al. (1998) Induction of apoptosis in vitro and in vivo by H-1 parvovirus infection. J Gen Virol 79 (Pt 12), 3067-3071,
90. Rayet, B. et al. (1998) Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J Virol 72, 8893-8903,
91. Moehler, M. et al. (2001) Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther 8, 158-167,
92. Haviv, Y.S. and Curiel, D.T. (2001) Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev 53, 135-154,
93. Galanis, E., Vile, R. and Russell, S.J. (2001) Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol 38, 177-192,
94. Chao, H. et al. (2000) Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2, 619-623,
95. Halbert, C.L. et al. (2000) Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 74, 1524-1532,
96. Zabner, J. et al. (2000) Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 74, 3852-3858,
97. Davidson, B.L. et al. (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 97, 3428-3432,
98. Hildinger, M. et al. (2001) Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 75, 6199-6203,
99. Xiao, W. et al. (1999) Gene therapy vectors based on adeno-associated virus type 1. J Virol 73, 3994-4003,
100. Lotery, A.J. et al. (2003) Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina. Hum Gene Ther 14, 1663-1671,
101. Rohr, U.P. et al. (2002) Primary human cells differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression. J Virol Methods 105, 265-275,
102. Rabinowitz, J.E. et al. (2002) Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76, 791-801,
103. Auricchio, A. et al. (2001) Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 10, 3075-3081,
104. Duan, D. et al. (2001) Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. J Virol 75, 7662-7671,
105. Pajusola, K. et al. (2002) Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J Virol 76, 11530-11540,
106. Summerford, C. and Samulski, R.J. (1998) Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72, 1438-1445,
107. Kaludov, N. et al. (2001) Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 75, 6884-6893,
108. Walters, R.W. et al. (2001) Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 276, 20610-20616,
109. Girod, A. et al. (1999) Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 5, 1052-1056,
110. Grifman, M. et al. (2001) Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 3, 964-975,
111. Wu, P. et al. (2000) Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 74, 8635-8647,
112. Shi, W., Arnold, G.S. and Bartlett, J.S. (2001) Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 12, 1697-1711,
113. Rabinowitz, J.E., Xiao, W. and Samulski, R.J. (1999) Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265, 274-285,
114. Nicklin, S.A. et al. (2001) Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 4, 174-181,
115. Shi, W. and Bartlett, J.S. (2003) RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 7, 515-525,
116. Loiler, S.A. et al. (2003) Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther 10, 1551-1558,
117. Perabo, L. et al. (2003) In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 8, 151-157,
118. Muller, O.J. et al. (2003) Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 21, 1040-1046,
119. Bartlett, J.S. et al. (1999) Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol 17, 181-186,
120. Ponnazhagan, S. et al. (2002) Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol 76, 12900-12907,
121. Maxwell, I.H. et al. (2001) Expansion of tropism of a feline parvovirus to target a human tumor cell line by display of an alpha(v) integrin binding peptide on the capsid. Gene Ther 8, 324-331,
122. Xiao, W. et al. (1998) Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 72, 10222-10226,
123. Gow, A., Friedrich, V.L., Jr. and Lazzarini, R.A. (1992) Myelin basic protein gene contains separate enhancers for oligodendrocyte and Schwann cell expression. J Cell Biol 119, 605-616,
124. Chen, H. et al. (1998) Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus. Gene Ther 5, 50-58,
125. Cucchiarini, M. et al. (2003) Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectors. Gene Ther 10, 657-667,
126. Maxwell, I.H. et al. (1996) Autonomous parvovirus transduction of a gene under control of tissue-specific or inducible promoters. Gene Ther 3, 28-36,
127. Maxwell, I.H. and Maxwell, F. (1999) Control of parvovirus DNA replication by a tetracycline-regulated repressor. Gene Ther 6, 309-313,
128. Malerba, M. et al. (2003) Replicating parvoviruses that target colon cancer cells. J Virol 77, 6683-6691,
129. Zhang, J. and Russell, S.J. (1996) Vectors for cancer gene therapy. Cancer Metastasis Rev 15, 385-401,
130. Waller, E.K. and Ernstoff, M.S. (2003) Modulation of antitumor immune responses by hematopoietic cytokines. Cancer 97, 1797-1809,
131. Brentjens, R.J. et al. (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9, 279-286,
132. Becknell, B. and Caligiuri, M.A. (2003) Cancer T cell therapy expands. Nat Med 9, 257-258,
133. Vile, R.G., Russell, S.J. and Lemoine, N.R. (2000) Cancer gene therapy: hard lessons and new courses. Gene Ther 7, 2-8,
134. Waldmann, T.A. (2003) Immunotherapy: past, present and future. Nat Med 9, 269-277,
135. Schlehofer, J.R., Rentrop, M. and Mannel D.N. (1992) Parvoviruses are inefficient in inducing interferon-beta, tumor necrosis factor-alpha, or interleukin-6 in mammalian cells. Med Microbiol Immunol (Berl) 181, 153-164,
136. Bantel-Schaal, U. (2001) Integration of adeno-associated virus 2 DNA in human MKR melanoma cells induces a peptide with oncosuppressive properties. Int J Cancer 92, 537-544,
137. Moehler, M. et al. (2003) Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells. Cancer Gene Ther 10, 477-480,
138. Anderson, K.M. and Srivastava, P.K. (2000) Heat, heat shock, heat shock proteins and death: a central link in innate and adaptive immune responses. Immunol Lett 74, 35-39,
139. Brunda, M.J. et al. (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178, 1223-1230,
140. Nastala, C.L. et al. (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153, 1697-1706,
141. Kawai, K. et al. (2000) Ex vivo gene therapy using granulocyte-macrophage colony-stimulating factor-transduced tumor vaccines. Mol Urol 4, 43-46,
142. Parmiani, G. et al. (2000) Cytokines in cancer therapy. Immunol Lett 74, 41-44,
143. Rosenberg, S.A. (2001) Progress in human tumour immunology and immunotherapy. Nature 411, 380-384,
144. Gansbacher, B. et al. (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172, 1217-1224,
145. Siapati, K.E. et al. (2003) Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer 88, 1641-1648,
146. Cameron, R.B., Spiess, P.J. and Rosenberg, S.A. (1990) Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med 171, 249-263,
147. Trinchieri, G. (1998) Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 16, 365-396,
148. Philip, R. et al. (1994) Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol Cell Biol 14, 2411-2418,
149. Vieweg, J. et al. (1995) Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 55, 2366-2372,
150. Coveney, E. et al. (1996) Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals. Surgery 120, 265-272; discussion 272-263,
151. Philip, R. et al. (1996) Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. Clin Cancer Res 2, 59-68,
152. Clary, B.M. et al. (1997) Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system. J Immunother 20, 26-37,
153. Russell, S.J. et al. (1992) Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol 66, 2821-2828,
154. Haag, A. et al. (2000) Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum Gene Ther 11, 597-609,
155. Bonecchi, R. et al. (1999) Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils. J Immunol 162, 474-479,
156. Dieu-Nosjean, M.C. et al. (1999) Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J Leukoc Biol 66, 252-262,
157. Allavena, P. et al. (1994) Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 24, 3233-3236,
158. Noso, N. et al. (1994) Human monocyte chemotactic proteins-2 and 3 (MCP-2 and MCP-3) attract human eosinophils and desensitize the chemotactic responses towards RANTES. Biochem Biophys Res Commun 200, 1470-1476,
159. Sozzani, S. et al. (1997) Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol 159, 1993-2000,
160. Taub, D.D. et al. (1995) Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 95, 1370-1376,
161. Alam, R. et al. (1994) Monocyte chemotactic protein-2, monocyte chemotactic protein-3, and fibroblast-induced cytokine. Three new chemokines induce chemotaxis and activation of basophils. J Immunol 153, 3155-3159,
162. Proost, P., Wuyts, A. and Van Damme, J. (1996) Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J Leukoc Biol 59, 67-74,
163. Rosl, F. et al. (1994) Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids. J Virol 68, 2142-2150,
164. Kleine, K. et al. (1995) The effect of the JE (MCP-1) gene, which encodes monocyte chemoattractant protein-1, on the growth of HeLa cells and derived somatic-cell hybrids in nude mice. Mol Carcinog 14, 179-189,
165. Kunke, D. et al. (2000) Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors. Cancer Gene Ther 7, 766-777,
166. Wetzel, K. et al. (2001) Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts. J Gene Med 3, 326-337,
167. Chen, L. et al. (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102,
168. Chen, L. et al. (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179, 523-532,
169. Townsend, S.E. and Allison, J.P. (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259, 368-370,
170. Townsend, S.E. et al. (1994) Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54, 6477-6483,
171. Matulonis, U.A. et al. (1995) Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85, 2507-2515,
172. Wu, T.C. et al. (1995) A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 182, 1415-1421,
173. Wendtner, C.M. et al. (1997) Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther 4, 726-735,
174. Nouri-Shirazi, M. et al. (2000) Dendritic cell based tumor vaccines. Immunol Lett 74, 5-10,
175. Chiriva-Internati, M. et al. (2002) Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/ human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol 32, 30-38,
176. Liu, Y. et al. (2001) Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther 8, 948-957,
177. Ponnazhagan, S. et al. (2001) Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol 75, 9493-9501,
178. Sun, J.Y. et al. (2002) Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res 62, 3175-3183,
179. Wildner, O., Blaese, R.M. and Candotti, F. (1999) Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res 59, 5233-5238,
180. Okada, H. et al. (1996) Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Ther 3, 957-964,
181. Giese, N.A. et al. (2002) Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther 9, 432-442,
182. Angiolillo, A.L. et al. (1995) Human interferoninducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182, 155-162,
183. Farber, J.M. (1997) Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 61, 246-257,
184. Nathwani, A.C. et al. (2001) Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 97, 1258-1265,
185. Ponnazhagan, S. et al. (2004) Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 64, 1781-1787,
186. Li, J. et al. (2003) Efficient and long-term intracardiac gene transfer in delta-sarcoglycandeficiency hamster by adeno-associated virus-2 vectors. Gene Ther 10, 1807-1813,
187. Flotte, T.R. et al. (1992) Gene expression from adeno-associated virus vectors in airway epithelial cells. Am J Respir Cell Mol Biol 7, 349-356,
188. Muro-Cacho, C.A., Samulski, R.J. and Kaplan, D. (1992) Gene transfer in human lymphocytes using a vector based on adeno-associated virus. J Immunother 11, 231-237,
189. Zhang P.X. and Fuleihan, R.L. (1999) Transfer of activation-dependent gene expression into T cell lines by recombinant adeno-associated virus. Gene Ther 6, 182-189,
190. Carrau, R.L. et al. (1995) Tumor angiogenesis as a predictor of tumor aggressiveness and metastatic potential in squamous cell carcinoma of the head and neck. Invasion Metastasis 15, 197-202,
191. Jaeger, T.M. et al. (1995) Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 154, 69-71,
192. Weidner, N. and Folkman, J. (1996) Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 167-190,
193. Dvorak, H.F. et al. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146, 1029-1039,
194. Ribatti, D., Vacca, A. and Dammacco, F. (2003) New non-angiogenesis dependent pathways for tumour growth. Eur J Cancer 39, 1835-1841,
195. Davis, D.W. et al. (2003) Antiangiogenic tumor therapy. Biotechniques 34, 1048-1050, 1052, 1054 passim,
196. Davidoff, A.M. et al. (2002) rAAV-mediated longterm liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Cancer Res 62, 3077-3083,
197. O'Reilly, M.S. et al. (1997) Endostatin: an endogenous inhibitor of
198. Dhanabal, M. et al. (1999) Endostatin induces endothelial cell apoptosis. J Biol Chem 274, 11721-11726,
199. Dhanabal, M. et al. (1999) Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59, 189-197,
200. Shi, W. et al. (2002) Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther 9, 513-521,
201. Eisterer, W. et al. (2002) Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Ther 5, 352-359,
202. Ried, M.U. et al. (2002) Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J Virol 76, 4559-4566,
203. Duverger, V. et al. (2002) Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2. Int J Cancer 97, 706-712,
204. Coker, A.L. et al. (2001) Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia. Exp Mol Pathol 70, 83-89,
205. Telerman, A. et al. (1993) A model for tumor suppression using H-1 parvovirus. Proc Natl Acad Sci U S A 90, 8702-8706,
206. Noteborn, M.H. et al. (1991) Characterization of cloned chicken anemia virus DNA that contains all elements for the infectious replication cycle. J Virol 65, 3131-3139,
207. Danen-Van Oorschot, A.A. et al. (2003) Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J Biol Chem 278, 27729-27736,
208. Leliveld, S.R. et al. (2003) Apoptin induces tumor-specific apoptosis as a globular multimer. J Biol Chem 278, 9042-9051,
209. Danen-van Oorschot, A.A., van Der Eb, A.J. and Noteborn, M.H. (2000) The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J Virol 74, 7072-7078,
210. Zhuang, S.M. et al. (1995) Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res 55, 486-489,
211. Danen-Van Oorschot, A.A. et al. (1997) Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci U S A 94, 5843-5847,
212. Olijslagers, S. et al. (2001) Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. Cancer Gene Ther 8, 958-965,
213. Dupont, F. et al. (2000) Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector. Gene Ther 7, 790-796,
214. Fruehauf, S. et al. (2002) Gene therapy for sarcoma. Cells Tissues Organs 172, 133-144,
215. Flasshove, M. et al. (2003) Hematoprotection by transfer of drug-resistance genes. Acta Haematol 110, 93-106,
216. Laufs, S. et al. (2003) Transfer of drug resistance genes in hematopoietic progenitors for chemoprotection: is it still an option? Drug Resist Updat 6, 57-69,
217. Halene, S. and Kohn, D.B. (2000) Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest. Hum Gene Ther 11, 1259-1267,
218. Strauss, L.C. et al. (1991) Selection of normal human hematopoietic stem cells for bone marrow transplantation using immunomagnetic microspheres and CD34 antibody. Am J Pediatr Hematol Oncol 13, 217-221,
219. Krause, D.S. et al. (1996) CD34: structure, biology, and clinical utility. Blood 87, 1-13,
220. Laver, J.H. et al. (1995) Characterization of c-kit expression by primitive hematopoietic progenitors in umbilical cord blood. Exp Hematol 23, 1515-1519,
221. Laver, J. et al. (1995) Effects of CD34+ selection and T cell immunodepletion on cord blood hematopoietic progenitors: relevance to stem cell transplantation. Exp Hematol 23, 1492-1496,
222. Grimm, D. et al. (1998) Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 9, 2745-2760,
223. Russell, D.W and Kay, M.A. (1999) Adeno-associated virus vectors and hematology. Blood 94, 864-874,
224. Chatterjee, S. et al. (1999) Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Blood 93, 1882-1894,
225. Baudard, M. et al. (1996) Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. Hum Gene Ther 7, 1309-1322,
226. Shaughnessy, E. et al. (1996) Parvoviral vectors for the gene therapy of cancer. Semin Oncol 23, 159-171,
227. Rabinowitz, J.E. and Samulski, R.J. (2000) Building a better vector: the manipulation of AAV virions. Virology 278, 301-308,
228. Kestler, J. et al. (1999) cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum Gene Ther 10, 1619-1632,
229. Brandenburger, A. et al. (1999) Influence of sequence and size of DNA on packaging efficiency of parvovirus MVM-based vectors. Hum Gene Ther 10, 1229-1238,
230. Nakai, H., Storm, T.A. and Kay, M.A. (2000) Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 18, 527-532,
231. Sun, L., Li, J. and Xiao, X. (2000) Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 6, 599-602,
232. Duan, D., Yue, Y. and Engelhardt, J.F. (2001) Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther 4, 383-391,